Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report

被引：3
|
作者：
Zhu, Lucheng [1 ,2 ]
Ma, Shenglin [1 ]
Xia, Bing [1 ,3 ]
机构：
[1] Zhejiang Univ, Affiliated Hangzhou Canc Hosp, Dept Thorac Oncol, Sch Med, Hangzhou, Peoples R China
[2] Zhejiang Chinese Med Univ, Affiliated Hangzhou Canc Hosp, Dept Oncol, Hangzhou, Peoples R China
[3] Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词：
ALK inhibitor; STRN-ALK fusion; thyroid cancer; alectinib; case report; VARIANT;
D O I：
10.3389/fonc.2022.1009076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Little is known about the efficacy of alectinib for papillary thyroid cancer with STRN-ALK fusion. A 64-year-old female presented with metastatic papillary thyroid cancer, widespread to lungs, mediastinal lymph nodes and brain 20 years after surgery. Disease progression still occurred after radioactive iodine therapy, chemotherapy, and radiotherapy. Tissue obtained from left cervical lymph node confirmed metastatic papillary thyroid cancer. Molecular profiling from re-biopsy tissue identified an STRN-ALK fusion rearrangement. After multidisciplinary discussion, alectinib was administered to the patient. Treatment was well tolerated, and follow-up images confirmed a partial response. ALK occurs rarely, with limited data suggesting the efficacy of ALK inhibitors in thyroid cancer. We presented the first case of a patient with PTC and STRN-ALK fusion to be treat effectively with alectinib.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] STRN-ALK Fusion-Positive Case of Breast Cancer With Response to Alectinib
    Kelly, Andrew D.
    Wiklund, Tom
    Kononen, Juha
    Creeden, James
    [J]. JCO PRECISION ONCOLOGY, 2021, 5 : 1281 - 1284
  • [2] STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
    Nagasaka, Misako
    Sarvadevabatla, Nagaratna
    Iwata, Shawn
    Ge, Yubin
    Sukari, Ammar
    Klosowski, Christian
    Yanagihara, Ronald
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (02):
  • [3] STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review
    Su, Cuiyun
    Jiang, Ya
    Jiang, Wei
    Wang, Huilin
    Liu, Sisi
    Shao, Yang
    Zhao, Wenhua
    Ning, Ruiling
    Yu, Qitao
    [J]. ONCOTARGETS AND THERAPY, 2020, 13 : 12515 - 12519
  • [4] Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib
    Nakanishi, Yoko
    Masuda, Shinobu
    Iida, Yuko
    Takahashi, Noriaki
    Hashimoto, Shu
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : E202 - E204
  • [5] Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion
    Li, Xiaoqing
    Zheng, Jingfan
    Li, Xinyi
    Chen, Yuyu
    Liu, Kang
    Li, Fangchao
    Lu, Zhong
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
    Zeng, Hao
    Li, Yalun
    Wang, Ye
    Huang, Meijuan
    Zhang, Yan
    Tian, Panwen
    Li, Weimin
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion
    Nikitski, Alyaksandr, V
    Rominski, Susan L.
    Wankhede, Mamta
    Kelly, Lindsey M.
    Panebianco, Federica
    Barila, Guillermo
    Altschuler, Daniel L.
    Nikiforov, Yuri E.
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2018, 188 (11): : 2653 - 2661
  • [8] Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer
    Kelly, Lindsey M.
    Barila, Guillermo
    Liu, Pengyuan
    Evdokimova, Viktoria N.
    Trivedi, Sumita
    Panebianco, Federica
    Gandhi, Manoj
    Carty, Sally E.
    Hodak, Steven P.
    Luo, Jianhua
    Dacic, Sanja
    Yu, Yan P.
    Nikiforova, Marina N.
    Ferris, Robert L.
    Altschuler, Daniel L.
    Nikiforov, Yuri E.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (11) : 4233 - 4238
  • [9] STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report
    Zhang, Linlin
    Xiao, Ping
    Meng, Fanlu
    Zhong, Diansheng
    [J]. CURRENT ONCOLOGY, 2022, 29 (10) : 6749 - 6753
  • [10] Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN-ALK Fusion In Vitro
    Ferrari, Silvia Martina
    Ragusa, Francesca
    Elia, Giusy
    Mazzi, Valeria
    Balestri, Eugenia
    Botrini, Chiara
    Rugani, Licia
    Patrizio, Armando
    Piaggi, Simona
    La Motta, Concettina
    Ulisse, Salvatore
    Virili, Camilla
    Antonelli, Alessandro
    Fallahi, Poupak
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)
12345